This study investigated the influence of CES1 variations, including the single nucleotide polymorphism (SNP) rs71647871 (G143E) and variation in copy number, on the pharmacokinetics of a single oral dose of 10 mg methylphenidate.
Introduction
Methylphenidate is a widely prescribed drug for attention deficit hyperactivity disorder (ADHD). From 2003 to 2013 the consumption of methylphenidate in Denmark has increased twentyfold [3] , and the same pattern has been observed in other developed countries [4, 5] . In the vast majority of formulations, methylphenidate is a racemic mixture consisting of equal amounts of d-and l-methylphenidate, which are metabolized almost exclusively by carboxylesterase 1 (CES1) to inactive d-and l-ritalinic acid, respectively. The biologically active compound is d-methylphenidate [6, 7] .
CES1 is an important enzyme found in large quantities in the human liver. It is estimated to be the tenth most abundant out of 6000 liver enzymes [8] , metabolizing ester-and amide-containing drugs and xenobiotics [9] . The gene encoding CES1 is located on chromosome 16, where four major haplotypes have been reported [10] (Figure 1 ). Various combinations of the haplotypes give rise to three different diplotypes with two, three or four copies of CES1. Two of the haplotypes contain a CES1-related pseudogene (CES1P1, Figure 1 CES1 gene loci on chromosome 16 spanning about 30 kbp. The four major CES1 haplotypes are designated (A-D). The vertical lines represent the exons of which there are 14. Light and dark green colours indicate regions derived from the original CES1A1 and the pseudogene, CES1P1, respectively also known as CES1A3 [10] ) which has six exons. CES1 is subject to duplication, and the duplicated CES1 variant is called CES1A2, while the original CES1 copy is designated CES1A1. The promoter region, exon 1, and the first part of intron 1 in CES1A2 are homologous to CES1P1, but apart from these regions CES1A1 and CES1A2 are identical [10] . A number of CES1A2 haplotypes exist; the most common variant of CES1A2 containing the CES1P1 promoter is transcribed to a lesser extent than CES1A1, but a variant with increased transcriptional activity has been reported [11] . In addition, there is a variant of CES1A1 designated CES1A1c by Tanimoto et al. [12] (also known as CES1VAR) in which exon 1 with flanking sequences has been replaced by the corresponding sequences of CES1P1. The CES1P1-derived segment in CES1A1c stretches into the Kozak sequence, thus potentially affecting the initiation of the translation.
Genetic variants affecting the function of CES1 might be important from a clinical point of view because the enzyme is responsible for metabolizing a wide range of drugs belonging to different therapeutic classes. Some of these medications are prodrugs, that are activated by CES1, including most of the angiotensin converting enzyme (ACE) inhibitors [13, 14] , dabigatran etexilate [15] , and oseltamivir [16] , while other drugs such as methylphenidate [17] and clopidogrel [18] are inactivated by CES1.
Variation in CES1 has the ability to affect the metabolism of methylphenidate, and thus contribute to the substantial individual variation in clinical response encountered when methylphenidate is used in therapy [19] . An example is the non-synonymous single nucleotide polymorphism (SNP) in CES1A1, rs71647871, also known as p.Gly143Glu or G143E, which creates a loss-of-function allele with markedly decreased enzymatic activity [20] . This SNP is located in exon 4 and results in a non-conservative substitution of glycine to glutamic acid. Its impact on the function of CES1 is well documented [21] [22] [23] . On the other hand, little is known about how duplication of CES1 influences drug metabolism.
The objective of this study was to investigate whether specific CES1 genotypes, including genotypes with duplication of the gene, affect the pharmacokinetic profile of methylphenidate in a population of healthy volunteers.
Methods

Selection of subjects and inclusion criteria
Two hundred healthy volunteers recruited from higher educational institutions were enrolled in this study (100 males and 100 females). After being given information about the study design and potential adverse reactions to the study drug, a written consent form was signed by each subject. The inclusion criteria were: healthy Caucasian males and females aged 18 or above. The exclusion criteria were: pregnancy; known allergy to the study drug; chronic medication apart from birth control devices, ear and eye drops, or creams against dermatitis; chronic disease including heart, liver, and kidney disease as well as high or low blood pressure; diabetes; smoking; and excessive alcohol consumption.
Screening and genotyping
Saliva samples were obtained from the 200 volunteers, and DNA for CES1 genotyping was extracted from the samples. The copy number of CES1, including the number of copies of CES1A1 and CES1A2, was determined by real-time duplex PCR. For samples with two CES1 copies, both CES1A1, two overlapping long range PCRs were carried out, allowing the amplification of all CES1A1 exons. The first of these long PCRs amplified a 12.5 kb fragment containing the promoter and exon 1-5 of the gene. The second amplified a 19.2 kb CES1A1 fragment containing exon 6-14. For samples with three or four copies, i.e. samples harbouring CES1A1 as well as CES1A2, the 12.5 kb fragment of CES1A1 and the corresponding CES1A2 were amplified. The long PCR for amplification of the CES1A1 fragment containing exon 6-14 does not distinguish CES1A1 from CES1A2 and was therefore not applicable for analysis of samples containing both these gene versions. Promoter and coding regions in the amplified fragments were subjected to Sanger sequencing. The sequences of the forward and reverse primers for amplification of the 12.5 kb fragment of CES1A1 were 5 0 -ACTATGGGGGGAC GGAGTTCA-3 0 and 5 0 -CCAGTCCTGAATTCAGGTATTGTA ATCA-3 0 . The 12.5 kb fragment of CES1A2 was amplified using the same reverse primer and a forward primer with the sequence 5 0 -CAGGAGCTATTGAGAGATGGAATCAT-3 0 . The 19.2 kb fragment of CES1A1 was amplified using a forward and reverse primer with the sequences 5 0 -CTGATTA CAATACCTGAATTCAGGAC-3 0 and 5 0 -GTATTTCTGCTCATT ATGGTCACG-3 0 , respectively. The amplifications were performed using Herculase Hotstart DNA Polymerase (Agilent Technologies, Santa Clara, CA, USA). Composition of reaction mixtures and temperature cycling were as recommended by the manufacturer of the DNA polymerase preparation with the exception that reaction mixtures for amplification of the 12.5 kb fragment of CES1A1 and CES1A2 were supplemented with an amount of MgCl 2 that increased the final concentration of this compound by 0.5 mM.
Selection of subjects for the drug trial
Based on the CES1 genotype, participants with presumed different metabolism were divided into the following predefined groups: Group 1, a control group (two copies of wild-type CES1A1, i.e. diplotype A/A without any non-synonymous SNPs in the exons, n = 17); group 2, a group with four copies of CES1 (two with diplotype B/D and three with diplotype B/B, no non-synonymous SNPs in exon 1-5, n = 5); group 3, a group harbouring the 143E allele (four with diplotype A/A and two with A/B, all heterozygous for the mutation, n = 6); group 4, a group having three copies of CES1, in which the duplication, CES1A2, had increased transcriptional activity (n = 2); group 5, a group with the CES1A1c variant (three with diplotype C/C and one with C/D, n = 4); and group 6, a group with three copies of CES1 in which the duplication, CES1A2, had the common promoter with low transcriptional activity (all with diplotype A/B, n = 10). Thus, the effect of having two, three or four copies of the gene, as well as having a duplication with increased transcriptional activity, was evaluated. In addition, we investigated the significance of the 143E allele, which has been shown to decrease the activity of CES1, and whether the CES1A1c variant is of importance. The genotype distributions of the population were in Hardy-Weinberg equilibrium.
Clinical study design
An open, prospective, uncontrolled, clinical trial involving the 44 subjects (19 males and 25 females) selected on the basis of CES1 genotype was undertaken. The subjects were not blinded to their genotype. Study medication was methylphenidate 10 mg in a single dose (Ritalin ® , Novartis, Basel, Switzerland). All participants were fasting overnight and the study drug was administered 1 h after a standardized breakfast. Two participants received a modified meal due to lactose intolerance and an error in the delivery from the kitchen. Serial blood samples for analysis of plasma concentrations of methylphenidate (d-and l-methylphenidate) and its metabolites (d-and l-ritalinic acid) were collected using a 5 ml Na-Flourid/Na-Heparin tube (Becton Dickinson) at 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24 and 33 h after dose administration. After centrifugation of the blood samples for 10 min at 3000 g and 4°C, the plasma was transferred to polypropylene screw-cap tubes and stored at À80°C until analysis of methylphenidate and ritalinic acid levels.
Pharmacokinetic variables
Non-compartmental methods were used to determine the pharmacokinetic variables of d-and l-methylphenidate as well as d-and l-ritalinic acid plasma concentrations. The pharmacokinetic variables were calculated using the PKSolver extension program (version 2.0) for Microsoft Excel and included AUC 0-inf , area under the concentration-time curve from time 0 to infinity; C max , the maximum concentration observed post dose; t max , time at which C max occurs; and t 1/2 , terminal elimination half-life. All AUCs were calculated by the linear-log trapezoidal method. Plasma concentrations below the limit of quantification (LOQ) were included as zero in the statistical analyses, and sampling times deviating more than 20% from the schedule were not included in the figure showing median concentrations on group level.
Analytical method d,l-Threo-methylphenidate was sourced from Lipomed (Arlesheim, Switzerland), d,l-threo-ritalinic acid was from Novartis (Basel, Switzerland), while internal standards d, l-threo-methylphenidate-d10 and d,l-threo-ritalinic acid-d10 were from Toronto Research Chemicals (Toronto, Canada). The concentrations of d-and l-threo isomers of methylphenidate and ritalinic acid in plasma were quantified by validated chiral high-pressure liquid chromatography-mass spectrometry using a Quattromicro tandem mass spectrometer (Waters, Milford, MA) operated in positive-ion electrospray mode and using multiple-reaction monitoring.
Plasma samples were prepared using solid-phase extraction as described for whole blood elsewhere [24] , but without the initial protein precipitation step. Chromatographic separation was performed using the same system as described elsewhere [24] . Briefly, a CHIRALPAK ® -AGP column (Sigma-Aldrich, St. Louis, MO) using isocratic elution was employed to separate the enantiomers of both analytes. The mobile phase consisted of 10 mM ammonium acetate with 0.4% isopropanol and 0.01% formic acid. Column temperature was 30°C and run-time 8 min. Precision and accuracy calculated from quality control samples included in each run were ≤9.1% and within ±9.7%, respectively, for all analytes.
Statistical analyses
Several groups had a small sample size and measurements that were not normally distributed graphically. Accordingly, nonparametric statistics were chosen and multiple regression with covariates other than genotype was omitted. The KruskalWallis test was used for analysis of variance. In case this analysis produced a significant P-value, the Mann-Whitney test was used for comparisons between the control group and each of the other five groups. For the assessment of the effect of gene duplications, a comparison between the group with four copies of CES1 and the group with three copies carrying the duplication with the common CES1A2 promoter was also performed. P-values were not adjusted for multiple comparisons as all statistical comparisons were defined a priori. A retrospective power calculation was performed using the formula for minimum sample size determination based on a single mean and standard deviation:
2 , in which z α is the two-tailed value of z related to α (generally α = 0.05), z β is the one-tailed value of z related to β (generally β = 0.20), σ is the standard deviation, and μ À μ 0 is the minimum relevant difference between the AUC of the control group and the other genotype groups [25] . Statistical analyses were conducted using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA). Differences were considered statistically significant when P < 0.05.
Results
Baseline characteristics of the 43 study participants and the different genotype groups are summarized in Table 1 . Apart from one subject, who caught a cold with fever, all participants completed the study according to the protocol, and no clinically significant adverse reactions were related to the administration of methylphenidate.
Frequency of the evaluated variants of CES1 in a Danish population
In the entire population of 200 Caucasian volunteers, the allele frequency of the haplotype carrying CES1A2 amounted to 14.7%. Five subjects (2.5%) carried two CES1A2 (i.e. four copies of CES1), and 48 subjects (24.4%) carried one CES1A2 (i.e. three copies of CES1). The promoter variant in CES1A2 that causes increased transcriptional activity was rare, being found in only two individuals corresponding to a frequency of 0.5% in the population. The frequency of the CES1A1 chimeric subtype, CES1A1c, was 15.5%. The 143E allele was detected in six individuals, who were all heterozygous for this allele, corresponding to an allele frequency of 1.6%. A detailed description of the diversity of the gene encoding CES1 in the overall population including the identification of novel gene variants is the subject of another study.
Effect of the genetic variations on the metabolism of methylphenidate
The pharmacokinetic results are shown in Table 2 . In terms of median AUC of d-methylphenidate (Figure 2 ), carrying the 143E allele was associated with a highly significant 149% increase in AUC compared to the control group (P < 0.0001). Subjects with four copies of CES1 had an increased median AUC of d-methylphenidate relative to the control group (61% increase, P = 0.011) and the group with three copies of CES1 carrying the common CES1A2 promoter (45% increase, P = 0.028). There was no difference when comparing the control group and the group with three CES1 copies carrying the common CES1A2 (P = 0.449). t max was not significantly different for any analytes. C max was significantly different for both d-methylphenidate (P = 0.004) and d-ritalinic acid (P = 0.0001) between the group carrying the 143E allele and the control group. In terms of t 1/2 , only 143E vs. control was significantly different (P = 0.0002) for d-methylphenidate.
Plasma concentrations of l-methylphenidate were below the limit of quantification (LOQ) at every time point for 38 out of 43 participants. Of the five subjects in whom l-methylphenidate was measurable, three participants carried the 143E allele. Compared to the group of controls, the groups with the CES1A1c and the CES1A2 variant with increased transcriptional activity showed no significant differences for any analytes. The group with four copies of CES1 contains an outlier having a d-methylphenidate AUC of 62.8 ng ml À1 t À1 . Exclusion of this subject in a post hoc analysis did not change the statistics, which still showed a significantly larger median (and mean) AUC compared to the control group. The pharmacokinetic data derived from the two subjects, who received a modified meal, were comparable to those receiving the standard meal. For the retrospective power calculation, we used the mean and standard deviation of d-methylphenidate AUC of the control group (21.86 ng ml À1 t À1 and 5.27 ng ml À1 t À1 , respectively, data not shown), a significance level of 5%, and a power of 80%. Based on this, we found that the number of subjects in each group required to detect a difference of 30% in the control group AUC was six (n > 5.06). The difference of 30% corresponded to a difference in mean AUC of 6.56 ng ml À1 t À1 . To detect a difference of 40%, only three subjects would be required.
Discussion
The present study investigated the impact of variation in CES1 on the metabolism of methylphenidate in healthy volunteers. It is the first study to investigate the impact of CES1 duplication on the metabolism of methylphenidate. Because of low promoter activity, the transcription of CES1A2 is approximately 2% of that of CES1A1 [26] . Consequently, one might expect the presence of CES1A2 to be without significance for drug metabolism. Surprisingly, we found that four copies of CES1 increased the AUC of d-methylphenidate compared to both two (control group) and three copies, reflecting a decreased CES1 activity. There was no difference when comparing the groups with two and three copies. This is in contrast to previously published literature. In a study of cancer patients receiving the cytotoxic drug irinotecan, Sai et al. [10] found a gene-dose effect of functional CES1 genes on the formation of the active irinotecan metabolite. Thus, subjects with three or four copies of the gene had an Control, two copies of wild-type CES1; 4 copies, four copies of CES1; G143E, subjects carrying the 143E allele; 3 copies active, three copies of CES1 in which CES1A2 has increased transcriptional activity; CES1A1c, subjects carrying the CES1A1c variant; 3 copies normal, three copies of CES1, in which CES1A2 possesses the common promoter.
increased CES1 activity compared to subjects with two copies of the gene. A study by Suzaki et al. [27] found no difference between subjects with three or four copies of CES1 in the metabolism of oseltamivir in 30 healthy Japanese volunteers. All subjects carried three or four copies of the gene, and therefore an estimate of the effect compared to subjects with no gene duplication is not obtainable. Lastly, a recent in vitro study of 102 normal human liver samples showed no significant differences in CES1 activity between two, three or four functional gene copies in the metabolism of enalapril [28] . Thus, with regard to duplication of CES1, our data diverge from previous studies which examined other substrates. In these studies, duplication had either no impact or an opposite effect to ours [10, 27, 28] .
It is possible that our finding of increased AUC in the group with four copies of CES1 reflects an undiscovered CES1A1 variant downstream of exon 5 in one or more of the subjects in this group and not an effect of the gene duplication. Due to sequence homology between CES1A1 and CES1A2, sequencing of all exons of CES1A1 was only possible in individuals with two copies of the gene. In individuals with three and four copies of the gene, a full sequence was only obtained for exons 1-5, and therefore the possibility of clinically significant SNPs downstream of the gene exists. This is supported by a previous study which reported nonsynonymous SNPs with a potential functional impact in CES1A1 exons downstream of exon 5 [29] .
The outlier in the group with four copies of CES1 might carry such an undiscovered functional gene variant. However, excluding the outlier from the statistical analysis did not change the significant differences. Thus, apart from a potential functional gene variant, there seems to be other reasons for the decreased enzymatic activity in the group with four copies of CES1. Such reasons include accidental differences in lifestyle having an impact on the activity of CES1.
The 143E allele was associated with a markedly decreased metabolism of methylphenidate, and this is in accordance with a previous finding [20] . It may not be possible to infer the effect of a change in plasma concentration on an individual level, but a median increase in AUC of 149%, as found in Table 2 Pharmacokinetic parameters on a group level Data are given as median (range). a Specific data for each subject. b Significantly (P < 0.05) different from three copies normal.
*/**/*** Significantly (P < 0.05/P < 0.005/P < 0.0005) different from control group. With regard to levo-methylphenidate, due to the fast metabolism there were not enough data to include it in the table.
Impact of CES1 genotype on methylphenidate pharmacokinetics our study, could warrant a dosage reduction due to adverse reactions. Tarkiainen et al. found a mean increase in oseltamivir AUC 0-inf of 18% and a mean decrease in enalaprilat AUC 0-inf of 20% in subjects heterozygous for the 143E allele compared to subjects carrying the wild-type genotype [22, 30] . Both results indicated a decreased enzymatic activity. Accordingly, this genetic variant appears to have a larger impact on the pharmacokinetics of methylphenidate than that of enalapril and oseltamivir. The subjects in our study were all heterozygous for the 143E allele, hindering an assessment of a genedosage effect. However, a subject homozygous for this allele has previously been associated with a significantly decreased metabolism of oseltamivir compared to heterozygous subjects, suggesting a gene-dosage effect [22] . A priori, the group with three copies of CES1, in which the duplication, CES1A2, had increased transcriptional activity was thought to have an increased metabolism of methylphenidate. In our population, this genetic variant was rare and the pharmacokinetic results of the two subjects with this genotype were alike in terms of AUC of d-methylphenidate but differed in terms of C max and t max . Overall, we found no indication that this promoter enhances the activity of the enzyme.
The CES1A1c group showed no pharmacokinetic differences for any analytes compared to the control group. This is consistent with a recent in vitro study in which human liver samples from individuals carrying the CES1A1c variant (CES1VAR) had a 2.6-fold lower mRNA expression compared to non-carriers but without detectable changes in protein expression and enzymatic activity [31] .
The first and most important limitation of this study is the small number of individuals in some of the genotype groups, which necessitate a cautious interpretation of the results. Studies estimating the impact of genetic polymorphism of genes on clinical or paraclinical outcomes are generally challenged by the fact that the most relevant alleles only occur at low frequencies. The small number of participants in our groups makes it difficult to correct for the impact of covariates like gender, age and BMI in our statistical analyses, which could have improved the ability to detect the effect of the genetic variants. However, our retrospective power calculation showed that a small subject number in each group is sufficient to detect a difference of 30% or more in d-methylphenidate AUC between our groups.
Secondly, we only used a single dose of methylphenidate. This hampers a direct translation of our results to the clinical environment, in which multiple dosage is the norm. A future study investigating the impact of CES1 genotypes on multiple dosage regimens is needed.
Before implementation of genotype guided therapy, it has to be established whether or not there is a correlation between plasma concentrations of methylphenidate and therapeutic response. Three previous studies describing the effect of methylphenidate on children with ADHD found no such correlation [32] , while two more recent studies have shown this correlation [33, 34] .
In summary, carrying the CES1 143E allele was found to have a substantial impact on the metabolism of methylphenidate, whereas CES1A1c did not appear to influence this metabolism. Moreover, our data revealed an unexpected and unexplained decrease in the metabolism of methylphenidate in subjects carrying four copies of CES1. More information about the functional CES1 variants may contribute to an optimized and personalized methylphenidate therapy.
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